Sanofi’s neurology pipeline has had a hole blown in it after a phase 3 trial of riliprubart in rare disease CIDP was stopped for futility.

May saw a drug ad spending slump across the majority of the top ten drug ad spenders with AbbVie’s Skyrizi and RInvoq, Johnson & Johnson’s

Patients with Lynch syndrome could have a potential treatment on the horizon, as a Moderna mRNA vaccine starts trials at Oxford University.

A survey has shown that UK doctors think AI can help them save time and expand their capacity to care for patients, but training is

AstraZeneca prepares to move its oral GLP-1 elecoglipron into phase 3 for obesity and diabetes, after reporting encouraging phase 2b data at ADA.